Mirati Therapeutics, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $12.4M | $72.1M | $13.4M | $3.3M | $12.9M | $0 |
| Operating income | −$759.6M | −$573.2M | −$369.4M | −$222.1M | −$102.6M | −$71.5M |
| Net income | −$740.9M | −$581.8M | −$357.9M | −$213.3M | −$98.4M | −$70.4M |
| Total assets | $1.20B | $1.59B | $1.48B | $432.2M | $228.5M | $157.2M |
| Total liabilities | $206.1M | $191.7M | $115.3M | $49.9M | $26.9M | $14.0M |
| Equity | $996.5M | $1.40B | $1.36B | $382.3M | $201.6M | $143.3M |
| EPS (diluted) | $-13.18 | $-11.21 | $-7.96 | $-5.69 | — | $-0.73 |
| Shares out. | 55.5M | 50.6M | 43.5M | 35.3M | 28.9M | 24.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −6108.0%
- Net margin
- −5957.4%
- Return on equity
- −74.3%
- Return on assets
- −61.6%
- Return on capital (ROCE)
- −72.8%
- Liabilities / assets
- 17.1%
- Debt / equity
- 0.21×
- Book value / share
- $17.96
- Revenue growth (YoY)
- −82.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -0.64distress
- Accruals / assets
- −14.2%clean
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2023-12-30Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
- Phase 3Active Not Recruitingreadout ~2026-01-16Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
- Phase 2Recruitingreadout ~2026-06-01Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
- Phase 2Active Not Recruitingreadout ~2026-07-30Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
- Phase 1/2Active Not Recruitingreadout ~2026-12-31Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
- Phase 2Recruitingreadout ~2028-02-16A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
- Phase 3Recruitingreadout ~2029-09-07A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Phase 2/3Recruitingreadout ~2032-06-09Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Boxer Capital, Llc | Jan 23, 2024 | D | 287,866 | — |
| Sharp ShaliniDirector | Jan 23, 2024 | D | 4,162 | — |
| Cherrington Julie MDirector | Jan 23, 2024 | D | 4,444 | — |
| Davis Aaron I.Director | Jan 23, 2024 | D | 43,073 | — |
| Carter Bruce L ADirector | Jan 23, 2024 | D | 6,021 | — |
| Johnson Craig ADirector | Jan 23, 2024 | D | 6,021 | — |
| Hasnain FaheemDirector | Jan 23, 2024 | D | 8,717 | — |
| Ondrey AaronOfficer — Chief Financial Officer | Jan 23, 2024 | D | 1,302 | — |
| Moriarty John BOfficer — Chief Legal Officer | Jan 23, 2024 | D | 675 | — |
| Hickey BenjaminOfficer — EVP, Chief Commercial Officer | Jan 23, 2024 | D | 27,801 | — |
| Martinez Maria EDirector | Jan 23, 2024 | D | 6,021 | — |
| Sandler Alan B.Officer — Chief Medical Officer | Jan 23, 2024 | D | 10,547 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventJan 23, 2024
- Other material eventDec 19, 2023
- Shareholder voteDec 13, 2023
- Other material eventNov 24, 2023
- Other material eventNov 13, 2023
- Results of operationsNov 6, 2023
- Entered a material agreement · Amended charter or bylaws · Other material eventOct 10, 2023
- Director / officer change · Regulation FD disclosureAug 23, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13GFeb 14, 2024
- SC 13G/AFeb 14, 2024
- SC 13G/AMIRATI THERAPEUTICS, INC.Feb 14, 2024
- SC 13G/AMIRATI THERAPEUTICS, INC.Feb 14, 2024
- SC 13G/ASCHEDULE 13G/AFeb 13, 2024
- SC 13G/AMS AMENDMENTFeb 9, 2024
- SC 13GMS INITIALFeb 9, 2024
- SC 13G/ASEC SCHEDULE 13GFeb 8, 2024
- 15-12GFeb 2, 2024
- SC 13GJan 31, 2024
- 4Jan 25, 2024
- SC 13D/AJan 25, 2024
- EFFECTJan 24, 2024
- EFFECTJan 24, 2024
- EFFECTJan 24, 2024
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.